RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: PL5
Target: Pancreatic ductal adenocarcinoma cell line (PL45)
Type of nucleic acid: ssDNA
Sequence: 5′CGCTCGGATGCCACTACAGCCAGCGTGGATATGGGTTCCACTGGTCACCGAGTCTGAGGCTGG3′
Sequence length: 63
GC content: 0.6190476190476191
Affinity: Kd: 65.5 ± 18.1 nM @37 
Pool type: 5′-CCAGCCTCAGACTCGGTGA-N25-TGTAGTGGCATCCGAGCG-3′
Pool random region: 25
Binding buffer/conditions: Dulbecco's phosphate buffered saline, glucose (4.5 g/L), 5 mM MgCl2, bovine serum albumin (1 mg/mL) and Transfer ribonucleotide acid (tRNA) (0.1 mg/mL)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpeutic: " Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection."
Reference (2015, Sci Rep ): Champanhac, C., Teng, I. T., Cansiz, S., Zhang, L., Wu, X., Zhoa, Z., Fu, T., & Tan, W. (2015). Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma. Scientific reports, 5, 16788. https://doi.org/10.1038/srep16788
Aptamer: PL6
Target: Pancreatic ductal adenocarcinoma cell line (PL45)
Type of nucleic acid: ssDNA
Sequence: 5′CGCTCGGATGCCACTACAGTACACACTGGTCTCAAGGGTGTGAGTCACCGAGTCTGAGGCTGG3′
Sequence length: 63
GC content: 0.5873015873015873
Affinity: Kd: 178.9 ± 30.1 nM @37C
Pool type: 5′-CCAGCCTCAGACTCGGTGA-N25-TGTAGTGGCATCCGAGCG-3′
Pool random region: 25
Binding buffer/conditions: Dulbecco's phosphate buffered saline, glucose (4.5 g/L), 5 mM MgCl2, bovine serum albumin (1 mg/mL) and Transfer ribonucleotide acid (tRNA) (0.1 mg/mL)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpeutic: " Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection."
Reference (2015, Sci Rep ): Champanhac, C., Teng, I. T., Cansiz, S., Zhang, L., Wu, X., Zhoa, Z., Fu, T., & Tan, W. (2015). Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma. Scientific reports, 5, 16788. https://doi.org/10.1038/srep16788
Aptamer: PL7
Target: Pancreatic ductal adenocarcinoma cell line (PL45)
Type of nucleic acid: ssDNA
Sequence: 5′CGCTCGGATGCCACTGTTGAGGTGTATTGTACACGTGGGGTTACACACCGAGTCTGAGGCTGG3′
Sequence length: 63
GC content: 0.5714285714285714
Affinity: Kd: 30.0 ± 11.2 nM @37C
Pool type: 5′-CCAGCCTCAGACTCGGTGA-N25-TGTAGTGGCATCCGAGCG-3′
Pool random region: 25
Binding buffer/conditions: Dulbecco's phosphate buffered saline, glucose (4.5 g/L), 5 mM MgCl2, bovine serum albumin (1 mg/mL) and Transfer ribonucleotide acid (tRNA) (0.1 mg/mL)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpeutic: " Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection."
Reference (2015, Sci Rep ): Champanhac, C., Teng, I. T., Cansiz, S., Zhang, L., Wu, X., Zhoa, Z., Fu, T., & Tan, W. (2015). Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma. Scientific reports, 5, 16788. https://doi.org/10.1038/srep16788
Aptamer: PL8
Target: Pancreatic ductal adenocarcinoma cell line (PL45)
Type of nucleic acid: ssDNA
Sequence: 5′CGCTCGGATGCCACTACAGCATATATCCTCCCCCCATGCGTGGTCACCGAGTCTGAGGCTGG3'
Sequence length: 62
GC content: 0.6129032258064516
Affinity: Kd: 26.1 ± 6.5 nM @37C
Pool type: 5′-CCAGCCTCAGACTCGGTGA-N25-TGTAGTGGCATCCGAGCG-3′
Pool random region: 25
Binding buffer/conditions: Dulbecco's phosphate buffered saline, glucose (4.5 g/L), 5 mM MgCl2, bovine serum albumin (1 mg/mL) and Transfer ribonucleotide acid (tRNA) (0.1 mg/mL)
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therpeutic: " Pancreatic cancer costs nearly 40,000 lives in the U.S. each year and has one of the lowest survival rates among cancers. Effective treatment of pancreatic ductal adenocarcinoma is hindered by lack of a reliable biomarker. The results show a viability of almost 80% for negative cells while only 50% of the target cells remained alive after 48 h incubation. These results lead to the conclusion that further research could reveal protein biomarkers specific to pancreatic adenocarcinoma, with probes available for early detection."
Reference (2015, Sci Rep ): Champanhac, C., Teng, I. T., Cansiz, S., Zhang, L., Wu, X., Zhoa, Z., Fu, T., & Tan, W. (2015). Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma. Scientific reports, 5, 16788. https://doi.org/10.1038/srep16788
Aptamer: CA72-4 A01
Target: Gastrointestinal cancer antigen 72–4
Type of nucleic acid: ssRNA
Sequence: 5'GGGUCGUGUCGGAUCCUGCGAAGGGGGGCAGAGGUUUGACGCGAGAAAGCUUCUAAGGUAACGAU3'
Sequence length: 65
GC content: 0.5692307692307692
Affinity: Kd: 52.7nM
Pool type: 5'-ATCGTTACCTTAGAAGCTT-N30-GGATCCGACACGACCCTATAGTGAGTCGTATTA-3'
Pool random region: 30
Binding buffer/conditions: RSB-100 buffer (10 mM Tris-HCl, 5 mM MgCl2, 100 mM NaCl, 0.01% NP-40, pH 7.5), 25C for 30 minutes
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: 20051.8 G/mol
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Gastric cancer is the third most common cause of death from cancer in the world and it remains difficult to cure in Western countries, primarily because most patients present with advanced disease. Currently, CEA, CA50 and CA72-4 are commonly used as tumor markers for gastric cancer by immunoassays. Taking together, these novel RNA aptamers targeting gastrointestinal cancer biomarker CEA, CA50 and CA72-4 will aid further development and standardization of clinical diagnostic method with better sensitivity and specificity, and potentially future therapeutics development of gastric cancer."
Reference (2015, PLoS One ): Pan, Q., Law, C., Yung, M., Han, K. C., Pon, Y. L., & Lau, T. (2018). Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity. PloS one, 13(10), e0198980. https://doi.org/10.1371/journal.pone.0198980
Aptamer: CA50 A01
Target: Gastrointestinal cancer antigen 50
Type of nucleic acid: ssRNA
Sequence: 5'GGGUCGUGUCGGAUCCGUGAGUUUUUCGCGGCGAAGACAAGGCUCGAAGCUUCUAAGGUAACGAU3'
Sequence length: 65
GC content: 0.5384615384615384
Affinity: Kd: 38 nM
Pool type: 5'-ATCGTTACCTTAGAAGCTT-N30-GGATCCGACACGACCCTATAGTGAGTCGTATTA-3'
Pool random region: 30
Binding buffer/conditions: RSB-100 buffer (10 mM Tris-HCl, 5 mM MgCl2, 100 mM NaCl, 0.01% NP-40, pH 7.5), 25C for 30 minutes
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 7.5
Molecular weight of target: 19967.6 G/mol
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Gastric cancer is the third most common cause of death from cancer in the world and it remains difficult to cure in Western countries, primarily because most patients present with advanced disease. Currently, CEA, CA50 and CA72-4 are commonly used as tumor markers for gastric cancer by immunoassays. Taking together, these novel RNA aptamers targeting gastrointestinal cancer biomarker CEA, CA50 and CA72-4 will aid further development and standardization of clinical diagnostic method with better sensitivity and specificity, and potentially future therapeutics development of gastric cancer."
Reference (2015, PLoS One ): Pan, Q., Law, C., Yung, M., Han, K. C., Pon, Y. L., & Lau, T. (2018). Novel RNA aptamers targeting gastrointestinal cancer biomarkers CEA, CA50 and CA72-4 with superior affinity and specificity. PloS one, 13(10), e0198980. https://doi.org/10.1371/journal.pone.0198980
Aptamer: Apta-7
Target: Cytokine (CK+, CK-) stimulated cells that cause Chronic Kidney Disease (CKD)
Type of nucleic acid: ssDNA
Sequence: 5′GCTGTGTGACTCCTGCAACCTGTATGGGGGTTGGGCGGGTGGGCTGGTGGTGCGCGAGGTTGCAGCTGTATCTTGTCTCC3′
Sequence length: 80
GC content: 0.625
Affinity: Kd: 82 ± 19 nM
Pool type: 5′- GCTGTGTGACTCCTGCAA-N43-GCAGCTGTATCTTGTCTCC-3′
Pool random region: 43
Binding buffer/conditions: 0.5 mg/mL BSA, 0.5 mg/mL salmon sperm DNA, 1 mM CaCl2, and 1 mM MgCl2 in 1× PBS, 95C for 5 mins
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Current diagnostic biomarkers (e.g., serum creatinine and urine albumin) are insufficient for prediction of the pathogenesis of the disease. To address this need, we applied a cell-SELEX (systematic evolution of ligands by exponential enrichment) approach and identified a series of DNA aptamers, which exhibit high affinity and selectivity for cytokine-stimulated cells, resembling some aspects of a CKD phenotype. These findings are consistent with binding and subsequent internalization of the aptamers into cytokine-stimulated cells. Thus, our study sets the stage for applying selected DNA aptamers as theragnostic reagents for the development of targeted therapies to combat CKD."
Reference (2015, Mol Ther Nucleic Acids ): Ranches, G., Lukasser, M., Schramek, H., Ploner, A., Stasyk, T., Mayer, G., Mayer, G., & Hüttenhofer, A. (2017). In Vitro Selection of Cell-Internalizing DNA Aptamers in a Model System of Inflammatory Kidney Disease. Molecular therapy. Nucleic acids, 8, 198–210. https://doi.org/10.1016/j.omtn.2017.06.018
Aptamer: Apta-1
Target: Cytokine (CK+, CK-) stimulated cells that cause Chronic Kidney Disease (CKD)
Type of nucleic acid: ssDNA
Sequence: 5′GCTGTGTGACTCCTGCAATGACCAGACGGGGTGGGTGGGCGGGCTGTCGGCTGGTCCTCGTGCAGCTGTATCTTGTCTCC3′
Sequence length: 80
GC content: 0.6375
Affinity: Kd: 46 ± 4 nM
Pool type: 5′- GCTGTGTGACTCCTGCAA-N43-GCAGCTGTATCTTGTCTCC-3′
Pool random region: 43
Binding buffer/conditions: 0.5 mg/mL BSA, 0.5 mg/mL salmon sperm DNA, 1 mM CaCl2, and 1 mM MgCl2 in 1× PBS, 95C for 5 mins
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Current diagnostic biomarkers (e.g., serum creatinine and urine albumin) are insufficient for prediction of the pathogenesis of the disease. To address this need, we applied a cell-SELEX (systematic evolution of ligands by exponential enrichment) approach and identified a series of DNA aptamers, which exhibit high affinity and selectivity for cytokine-stimulated cells, resembling some aspects of a CKD phenotype. These findings are consistent with binding and subsequent internalization of the aptamers into cytokine-stimulated cells. Thus, our study sets the stage for applying selected DNA aptamers as theragnostic reagents for the development of targeted therapies to combat CKD."
Reference (2015, Mol Ther Nucleic Acids ): Ranches, G., Lukasser, M., Schramek, H., Ploner, A., Stasyk, T., Mayer, G., Mayer, G., & Hüttenhofer, A. (2017). In Vitro Selection of Cell-Internalizing DNA Aptamers in a Model System of Inflammatory Kidney Disease. Molecular therapy. Nucleic acids, 8, 198–210. https://doi.org/10.1016/j.omtn.2017.06.018
Aptamer: Apta-4
Target: Cytokine (CK+, CK-) stimulated cells that cause Chronic Kidney Disease (CKD)
Type of nucleic acid: ssDNA
Sequence: 5′GCTGTGTGACTCCTGCAAGACGCCGGGTTGGGTGGGTGGGAAGGGCGTCGCTCCCTCTTCGGCAGCTGTATCTTGTCTCC3′
Sequence length: 80
GC content: 0.6375
Affinity: Kd: 69 ± 27 nM
Pool type: 5′- GCTGTGTGACTCCTGCAA-N43-GCAGCTGTATCTTGTCTCC-3′
Pool random region: 43
Binding buffer/conditions: 0.5 mg/mL BSA, 0.5 mg/mL salmon sperm DNA, 1 mM CaCl2, and 1 mM MgCl2 in 1× PBS, 95C for 5 mins
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " Current diagnostic biomarkers (e.g., serum creatinine and urine albumin) are insufficient for prediction of the pathogenesis of the disease. To address this need, we applied a cell-SELEX (systematic evolution of ligands by exponential enrichment) approach and identified a series of DNA aptamers, which exhibit high affinity and selectivity for cytokine-stimulated cells, resembling some aspects of a CKD phenotype. These findings are consistent with binding and subsequent internalization of the aptamers into cytokine-stimulated cells. Thus, our study sets the stage for applying selected DNA aptamers as theragnostic reagents for the development of targeted therapies to combat CKD."
Reference (2015, Mol Ther Nucleic Acids ): Ranches, G., Lukasser, M., Schramek, H., Ploner, A., Stasyk, T., Mayer, G., Mayer, G., & Hüttenhofer, A. (2017). In Vitro Selection of Cell-Internalizing DNA Aptamers in a Model System of Inflammatory Kidney Disease. Molecular therapy. Nucleic acids, 8, 198–210. https://doi.org/10.1016/j.omtn.2017.06.018
Aptamer: RLA01
Target: Caov-3 epithelial ovarian tumor
Type of nucleic acid: ssDNA
Sequence: 5'CTCCTCTGACTGTAACCACGCGGAAAGCATCAGGGTTGAGCATAGGTAGTCCAGAAGCCA3'
Sequence length: 60
GC content: 0.5333333333333333
Affinity: Kd: 365.3 ± 24.14 nM
Pool type: 5′-CTCCTCTGACTGTAACCACG-N20-GCATAGGTAGTCCAGAAGCCA-3′
Pool random region: 20
Binding buffer/conditions: (100 μM) in Tris-EDTA (TE), 4.5 g/L glucose, 5mM MgCl2, 95C for 5 minutes
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " The objective of this work was to identify ovarian tumor-specific single-stranded DNA aptamers that bind to malignant ovarian tumor cells and internalize with high affinity and specificity. Aptamers showed unique binding affinities with apparent dissociation constants (Kd) measuring in the submicromolar range supporting their physiological relevance and potential use in clinical applications."
Reference (2015, Nucleic Acid Ther ): Benedetto, G., Hamp, T. J., Wesselman, P. J., & Richardson, C. (2015). Identification of epithelial ovarian tumor-specific aptamers. Nucleic acid therapeutics, 25(3), 162–172. https://doi.org/10.1089/nat.2014.0522
Aptamer: Q1
Target: Fluoroquinolones
Type of nucleic acid: ssDNA
Sequence: 5'ATACCAGCTTATTCAATTCGATGGTAAGTGAGGTTCGTCCCTTTAATAAACTCGATTAGGATCTCGTGAGGTGTGCTCTACAATCGTAATCAGTTAG3'
Sequence length: 97
GC content: 0.4020618556701031
Affinity: Kd: 56.9 ± 11.3 nM
Pool type: 5′-ATACCAGCTTATTCAATT-N10-TGAGGCTCGATC-N40-ACAATCGTAATCAGTTAG-3′
Pool random region: 50
Binding buffer/conditions: Binding buffer (100 mM NaCl, 20 mM Tris–HCl pH 7.6, 2 mM MgCl2, 1 mM CaCl2)
Divalent salt: MgCl/CaCl
Buffer type: Tris Buffers
pH: 7.6
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor: " Quinolones are antibiotics that are accredited in human and veterinary medicine but are regularly used in high quantities also in industrial livestock farming. Using the Capture-SELEX procedure, we here describe the selection of an aptamer pool with enhanced binding qualities for fluoroquinolones, a widely used group of antibiotics in both human and veterinary medicine. Together, our data suggest that these aptamers may be applicable as molecular receptors in biosensors or as catcher molecules in filter systems for improved monitoring and treatment of polluted water."
Additional information: 5′fluorescein (FAM) labeled
Reference (2015, Biosens Bioelectron ): Reinemann, C., Freiin von Fritsch, U., Rudolph, S., & Strehlitz, B. (2016). Generation and characterization of quinolone-specific DNA aptamers suitable for water monitoring. Biosensors & bioelectronics, 77, 1039–1047. https://doi.org/10.1016/j.bios.2015.10.069
Aptamer: CA125.1
Target: Cancer antigen 125 (CA125) tumor marker
Type of nucleic acid: 2'-fluoro-RNA
Sequence: 5′UAAUACGACUCACUAUAGGGAGACAAGAAUAAACGCUCAAAAAAUGCAUGGAGCGAAGGUGUGGGGGAUACCAACCGCGCCGUGUUGAGCGUUUAUUCUUGUCUCCCUAUAGUGAGUCGUAUUA3′
Sequence length: 124
GC content: 0.4516129032258064
Affinity: Kd: 4.13 nM
Pool type: 5′-TAATACGACTCACTATAGGGAGACAAGAATAAACGCTCAA-N45-TTGAGCGTTTATTCTTGTCTCCCTATAGTGAGTCGTATTA-3′
Pool random region: 45
Binding buffer/conditions: HBS-EP buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20)
Buffer type: Other Buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Early identification of neoplastic diseases is essential to achieve timely therapeutic interventions and significantly reduce the mortality of patients. A well-known biomarker is the Cancer Antigen 125 (CA125) or 16 mucin (MUC 16), a glycoprotein of the human family of mucins, already used for the diagnostic and prognostic evaluation of ovarian cancer. In this paper, we describe the development of RNA aptamers that bind with high affinity the tumor antigen CA125. The selected aptamers were cloned and sequenced and the binding properties of the most promising sequences were studied by Real Time PCR and Surface Plasmon Resonance (SPR) to evaluate their ability in targeting CA125 protein with perspective applications in aptamer-based bioassays."
Additional information: 2'-Fluoro-Pyrimidine modified nucleotides. 
To select high affinity aptamers for CA125 biomarker, we performed an in vitro protein SELEX by using human CA125 recombinant protein as target, with a C-terminal His tag as modification.
Reference (2015, Methods ): Lamberti, I., Scarano, S., Esposito, C. L., Antoccia, A., Antonini, G., Tanzarella, C., De Franciscis, V., & Minunni, M. (2016). In vitro selection of RNA aptamers against CA125 tumor marker in ovarian cancer and its study by optical biosensing. Methods (San Diego, Calif.), 97, 58–68. https://doi.org/10.1016/j.ymeth.2015.10.022
Aptamer: Mtb36
Target: Mycobacterium tuberculosis (M. tuberculosis) H37Ra
Type of nucleic acid: ssDNA
Sequence: 5′CCGTCAGCCGAGGACCACACTTGGTTGCTGAATCCCCTCGTCTTGGCTTTCTTTTGGGTGCAATGAAT3′
Sequence length: 68
GC content: 0.5294117647058824
Affinity: Kd: 5.09 ±1.43 nM
Pool type: 5′-CCGTCAGCCGAGGACCACAC-N40-TTGGGTGCAATGAAT-3′
Pool random region: 40
Binding buffer/conditions: PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, pH 7.4) and PBST (0.05 % Tween 20 in PBS)
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor and Diagnostic: "Tuberculosis (TB) remains to be a major global health problem, with about 9 million new cases and 1.4 million deaths in 2011. Aptamers are promising tools for developing point-of-care diagnostic assays for TB. In this study, ssDNA aptamers that recognize Mycobacterium tuberculosis H37Ra were selected by systematic evolution of ligands by exponential enrichment (SELEX). Mtb36 aptamer is highly selective for M. tuberculosis, and it can be used in an aptamer-based biosensor for the detection of M. tuberculosis."
Reference (2015, Appl Biochem Biotechnol ): Mozioglu, E., Gokmen, O., Tamerler, C., Kocagoz, Z. T., & Akgoz, M. (2016). Selection of Nucleic Acid Aptamers Specific for Mycobacterium tuberculosis. Applied biochemistry and biotechnology, 178(4), 849–864. https://doi.org/10.1007/s12010-015-1913-7
Aptamer: DNA01
Target: Palladium ion
Type of nucleic acid: ssDNA
Sequence: 5′CGTACGGAATTCGCTAGCGGGCGGACGCTAGGTGGTGATGCTGTGCTACACGTGTTGTGGATCCGAGCTCCACGTG3′
Sequence length: 76
GC content: 0.6052631578947368
Affinity: Kd: 4.60 ± 1.17 μM
Pool type: 5′-CGTACGGAATTCGCTAGC-N40-GGATCCGAGCTCCACGTG-3′
Pool random region: 40
Binding buffer/conditions: HEPES (0.1 M) at pH 8.02
Buffer type: Other Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " A new aptamer selection method using graphene oxide (GO)-adsorbed nanoparticles (GO-adsorbed NPs) was employed for specific fishing of palladium ion. Results of the present study suggest that future modification of DNA01 may improve palladium ion-binding ability, leading to economic recovery of palladium from water solution."
Reference (2015, Bioorg Med Chem Lett ): Cho, Y. S., Lee, E. J., Lee, G. H., & Hah, S. S. (2015). Aptamer selection for fishing of palladium ion using graphene oxide-adsorbed nanoparticles. Bioorganic & medicinal chemistry letters, 25(23), 5536–5539. https://doi.org/10.1016/j.bmcl.2015.10.056
Aptamer: DNA02
Target: Palladium ion
Type of nucleic acid: ssDNA
Sequence: 5′CGTACGGAATTCGCTAGCACAAGGGGTGCAGGGGTCCGCGATTGTGACTGTGTGTGCGGGATCCGAGCTCCACGTG3′
Sequence length: 76
GC content: 0.618421052631579
Affinity: Not reported
Pool type: 5′-CGTACGGAATTCGCTAGC-N40-GGATCCGAGCTCCACGTG-3′
Pool random region: 40
Binding buffer/conditions: HEPES (0.1 M) at pH 8.02
Buffer type: Other Buffers
pH: 8
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection: " A new aptamer selection method using graphene oxide (GO)-adsorbed nanoparticles (GO-adsorbed NPs) was employed for specific fishing of palladium ion. Results of the present study suggest that future modification of DNA01 may improve palladium ion-binding ability, leading to economic recovery of palladium from water solution."
Reference (2015, Bioorg Med Chem Lett ): Cho, Y. S., Lee, E. J., Lee, G. H., & Hah, S. S. (2015). Aptamer selection for fishing of palladium ion using graphene oxide-adsorbed nanoparticles. Bioorganic & medicinal chemistry letters, 25(23), 5536–5539. https://doi.org/10.1016/j.bmcl.2015.10.056